GLP-1 RA should be considered in all when no contraindications are present before initiation of insulin therapy, as they allow lower glycaemic targets to be reached with a lower injection burden and lower risk of hypoglycaemia and weight gain than with insulin alone
The Phase 2 VISTA trial demonstrated that Elecoglipron (AZD5004), a once-daily oral small-molecule GLP-1 receptor agonist, achieved up to 11.8% mean weight loss at 36 weeks in adults with obesity or overweight without diabetes
18F-FDG PET of common enhancing malignant brain tumors
Symptoms often include a rapid onset of masculine features, excessive hair growth, and a mass in the abdomen or pelvis
does metformin cause weight loss
When used alongside a good diet and exercise regimen, this medication has been proven to be effective for long term weight loss and reducing the risk of certain chronic metabolic conditions